fda warning letters glp-1 compounders september 2025 warns telehealth providers over obesity drug marketing fda glp-1 compounding warning letters

Pre-clinical safety characterisation studies have documented a favourable safety profile for both BPC-157 and TB-500 across the dose ranges studied in rodent models

Watch-outs to know: The FDA has flagged Semax as a peptide that might trigger an unwanted immune response, and it has raised concerns about impurity and lack of safety data in humans

10.1038/373699a0 101 ShengH.ShaoJ.TownsendC

It is an experimental compound that has been investigated for inflammatory bowel disease and soft tissue healing, although there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without any published conclusions

Turchi, R

How does Ipamorelin compare to other growth hormone-releasing peptides